We are live on ! Find out more
AAP

Ardsley Advisory Partners Portfolio holdings

AUM $960M
1-Year Est. Return 207.76%
This Fund
S&P 500
This Quarter Est. Return
+2.83%
1 Year Est. Return
+207.76%
3 Year Est. Return
+554.53%
5 Year Est. Return
+728.66%
10 Year Est. Return
+4,084.52%
AUM
$823M
AUM Growth
+$71.1M
Cap. Flow
+$54.2M
Cap. Flow %
6.59%
Top 10 Hldgs %
50.09%
Holding
190
New
61
Increased
39
Reduced
31
Closed
53

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$19.1M
2
MAC icon
Macerich
MAC
+$12.1M
3
EVA
Enviva Inc.
EVA
+$9.8M
4
OKTA icon
Okta
OKTA
+$8.15M
5
PEGI
Pattern Energy Group Inc. Class A
PEGI
+$7.71M

Top Sells

Rank Stock Value
1
RITM icon
Rithm Capital
RITM
+$19.4M
2
ZBH icon
Zimmer Biomet
ZBH
+$12.9M
3
ORCL icon
Oracle
ORCL
+$12.8M
4
URI icon
United Rentals
URI
+$10.4M
5
CIO
City Office REIT
CIO
+$10.1M

Sector Composition

Rank Sector Weight
1 Healthcare 15.81%
2 Technology 10.73%
3 Utilities 6.45%
4 Materials 4.95%
5 Energy 4.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
NVTR
126
DELISTED
Nuvectra Corporation Common Stock
NVTR
$171K 0.02%
22,095
APEN
127
DELISTED
Apollo Endosurgery, Inc.
APEN
$161K 0.02%
28,800
+10,000
+53% +$45.5K
P
128
Everpure Inc
P
$23.3B
$159K 0.02%
+10,000
New +$167K
CDNA icon
129
CareDx
CDNA
$1.84B
$147K 0.02%
+20,000
New +$125K
OXFD
130
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$140K 0.02%
10,000
-5,000
-33% -$73.2K
MGNI icon
131
Magnite
MGNI
$2.85B
$131K 0.02%
+70,000
New +$175K
IBRX icon
132
ImmunityBio
IBRX
$7.12B
$112K 0.01%
+25,000
New +$118K
CASC
133
DELISTED
Cascadian Therapeutics, Inc.
CASC
$93K 0.01%
+25,000
New +$102K
HROW icon
134
Harrow
HROW
$1.45B
$85K 0.01%
50,000
+30,000
+150% +$50K
LPCN icon
135
Lipocine
LPCN
$17.3M
$34K ﹤0.01%
+588
New +$36.6K
CFRX
136
DELISTED
ContraFect Corporation
CFRX
$15K ﹤0.01%
+19
New +$15.7K
ACRS icon
137
Aclaris Therapeutics
ACRS
$709M
-20,000
Closed -$516K
AMAT icon
138
Applied Materials
AMAT
$354B
-15,000
Closed -$781K
ANDE icon
139
Andersons Inc
ANDE
$2.4B
-20,000
Closed -$685K
BABA icon
140
Alibaba
BABA
$276B
-47,000
Closed -$8.12M
CIO
141
DELISTED
City Office REIT
CIO
-730,000
Closed -$10.1M
CRM icon
142
Salesforce
CRM
$154B
-4,000
Closed -$374K
CSIQ icon
143
CALL
Canadian Solar
CSIQ
$925M
-100,000
Closed -$1.68M
CSTM icon
144
Constellium
CSTM
$3.8B
-25,000
Closed -$256K
CTLP
145
DELISTED
Cantaloupe
CTLP
-1,195,000
Closed -$7.47M
EA icon
146
Electronic Arts
EA
$52.4B
-2,000
Closed -$236K
EXPE icon
147
Expedia Group
EXPE
$36.7B
-46,500
Closed -$6.69M
FDX icon
148
CALL
FedEx
FDX
$73.3B
-40,100
Closed -$9.05M
FDX icon
149
FedEx
FDX
$73.3B
-37,550
Closed -$8.47M
FLEX icon
150
Flex
FLEX
$37.8B
-37,156
Closed -$464K

Similar funds

Ardsley Advisory Partners's Q4 2017 Portfolio in Review

As of Q4 2017, Ardsley Advisory Partners held 190 positions worth $823M, up 9.5% from $752M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Ardsley Advisory Partners deployed $54.2M of net new capital in Q4 2017, opening 61 new positions and adding to 39 existing holdings. Its largest new stake was Macerich: 198,500 shares worth $13M.

By sector, the portfolio is most concentrated in Healthcare at 16% of assets, down from 17% a quarter earlier, followed by Technology and Utilities.

On the sell side, the largest reduction was PARSLEY ENERGY INC, an estimated $9.35M trimmed.

  • Ardsley Advisory Partners's largest Q4 2017 buy was Macerich: 198,500 shares worth $13M.
  • Ardsley Advisory Partners added most to AbbVie in Q4 2017, an estimated $19.1M increase.
  • Ardsley Advisory Partners's biggest Q4 2017 reduction was PARSLEY ENERGY INC, cutting an estimated $9.35M.
  • Ardsley Advisory Partners fully exited Rithm Capital in Q4 2017, selling an estimated $19.4M.
  • Ardsley Advisory Partners's ten largest holdings make up 50% of its $823M portfolio in Q4 2017.
  • Ardsley Advisory Partners opened 61 new positions and closed 53 in Q4 2017.
  • Ardsley Advisory Partners's portfolio value rose 9.5% quarter-over-quarter to $823M.

Based on Ardsley Advisory Partners's 13F filing for Q4 2017, filed 14 Feb 2018.